Skip to main content
. 2011 Jun 15;6(6):e20971. doi: 10.1371/journal.pone.0020971

Figure 4. Expression of PLEK2 and C1QB in fractionated blood of melanoma patients and healthy control individuals.

Figure 4

Freshly collected blood cells were fractionated into CD45+ and CD45− cells using whole blood CD45 kit, and analyzed by standard qRT-PCR. The expression of signature gene PLEK2 in CD45− subsets was compared between healthy individuals (n = 20) and melanoma patients (n = 20) (A) and melanoma from stage I (n = 8), stage II (n = 3), stage III (n = 3) and stage IV (n = 6) (B). The expression of signature gene C1QB in CD45+ subsets was compared between healthy individuals (n = 20) and melanoma patients (n = 20) (C) and melanoma from stage I (n = 8), stage II (n = 3), stage III (n = 3) and stage IV (n = 6) (D). The data are shown as the means ± S.E. ***, p<0.001 compared with control.